Literature DB >> 11907062

Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D.

Adelheid Cerwenka1, Christopher A O'Callaghan, Jessica A Hamerman, Rajwardhan Yadav, Wilfred Ajayi, Derry C Roopenian, Sebastian Joyce, Lewis L Lanier.   

Abstract

Minor histocompatibility Ags elicit cell-mediated immune responses and graft rejection in individuals receiving MHC-matched tissues. H60 represents a dominant Ag that elicits a strong CTL response in C57BL/6 mice immunized against BALB.B. An 8-aa peptide in the H60 protein is presented by H-2K(b) and this is recognized by the TCR as an alloantigen. The intact H60 glycoprotein is a ligand for the costimulatory NKG2D receptor that is expressed by activated CD8(+) T cells. Thus, H60 may provide both an allogeneic peptide and its own costimulation. We show that mutation of an H-2K(b)-binding anchor residue in the H60 peptide completely abrogates binding of H60 glycoprotein to NKG2D and a synthetic H60 peptide partially blocks the binding of NKG2D to its ligand. Ligands of the human NKG2D receptor are remarkably polymorphic, suggesting that these may also serve as minor histocompatibility Ags.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907062     DOI: 10.4049/jimmunol.168.7.3131

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.

Authors:  Barry J Kappel; Javier Pinilla-Ibarz; Adam A Kochman; Jeffrey M Eng; Vanessa M Hubbard; Ingrid Leiner; Eric G Pamer; Glen Heller; Marcel R M van den Brink; David A Scheinberg
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

2.  DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.

Authors:  He Zhou; Yunping Luo; Jeng-fan Lo; Charles D Kaplan; Masato Mizutani; Noriko Mizutani; Jiing-Dwan Lee; F James Primus; Jürgen C Becker; Rong Xiang; Ralph A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

3.  Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.

Authors:  Deepak Yadav; Jennifer Ngolab; Natalie Dang; Jack D Bui
Journal:  Immunology       Date:  2011-03-25       Impact factor: 7.397

4.  Polymorphisms of NKG2D ligands: diverse RAET1/ULBP genes in northeastern Thais.

Authors:  Amornrat V Romphruk; Arunrat Romphruk; Taeko K Naruse; Sarayot Raroengjai; Chintana Puapairoj; Hidetoshi Inoko; Chanvit Leelayuwat
Journal:  Immunogenetics       Date:  2009-08-18       Impact factor: 2.846

5.  Kinetics of gene expression in murine cutaneous graft-versus-host disease.

Authors:  Philip B Sugerman; Sara B Faber; Lucy M Willis; Aleksandra Petrovic; George F Murphy; Jacques Pappo; David Silberstein; Marcel R M van den Brink
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

6.  Enhancement of Antigen Presentation by Deletion of Viral Immune Evasion Genes Prevents Lethal Cytomegalovirus Disease in Minor Histocompatibility Antigen-Mismatched Hematopoietic Cell Transplantation.

Authors:  Emin Gezinir; Jürgen Podlech; Kerstin M Gergely; Sara Becker; Matthias J Reddehase; Niels A W Lemmermann
Journal:  Front Cell Infect Microbiol       Date:  2020-06-09       Impact factor: 5.293

Review 7.  H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.

Authors:  Eun Young Choi; Kyungho Choi; Giri Nam; Woojin Kim; Minho Chung
Journal:  Front Immunol       Date:  2020-06-10       Impact factor: 7.561

8.  NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules.

Authors:  Melissa Lodoen; Kouetsu Ogasawara; Jessica A Hamerman; Hisashi Arase; Jeffrey P Houchins; Edward S Mocarski; Lewis L Lanier
Journal:  J Exp Med       Date:  2003-05-19       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.